Breaking Finance News

Regeneron Pharmaceuticals Shares Rise On Drug Results

Sanofi-RegeneronRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEX: SAN and NYSE: SNY) announced  they will will begin a Phase II proof-of-concept study of the drug dupilumab. Regeneron Pharmaceutical stock climbed 1.57% to close at $360.52 per share while stock for Sanofi increased 1.29% to $56.43 per share.

This investigational therapy helps block two proteins linked to inflammation, interleukin-13 (IL-13) and interleukin-4 (IL-4), that benefits people with moderate-to-severe chronic sinusitis with nasal polyps and those who had little to no response to the more standard treatment of intranasal corticosteroids.

According to Dr. Gianluca Pirozzi, Vice President and Global Project Head of Sanofi, data gathered suggests that in addition to its initial purpose of treating chronic sinusitis coupled with nasal polyps, as well as related symptoms such as facial pain, congestion, reduced sense of smell, and sleep disruption, dupilumab could help patients with atopic dermatitis and asthma.

The double-blind placebo-controlled study consisted of 60 adults who had a moderate-to-severe level of this disease. As a result of using patient information but also data comprised from Phase II in which dupilumab was used to treat secondary conditions, blocking the two protein pathways using dupilumab was supported.

Regeneron is an integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines designed to treat serious medical conditions. Dupilumab if approved would join two other major Regeneron drugs to include injectable afilbercept and rilonacept.

Sanofi, which was formally called Sanofi-Aventis, is a diversified and global healthcare company that discovers and distributes therapeutic solutions based on patient need. Sanofi focuses primarily on seven growth platforms to include human vaccines, diabetes solutions, rare diseases, innovative drugs, emerging markets, consumer healthcare, and even animal health.

Using Regeneron’s pioneering Veloclmmune technology and in conjunction with Sanofi, dupilumab is being co-developed for chronic sinusitis with nasal polyps, asthma, and atopic dermatitis. Dupilumab is a breakthrough treatment with few side effects. Details of the study’s findings will be presented at a medical conference, followed by Sanofi pursuing additional clinical trials and gaining FDA approval.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.